Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications

References

• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440.
   PubMed Web of Science ®Google Scholar
• Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2:566–572.
   PubMed Web of Science ®Google Scholar
• Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014;11:1176–1185.
   PubMedGoogle Scholar
• Richeldi L. du Bois RM, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
   PubMed Web of Science ®Google Scholar
• Ingber DE. Cellular mechanotransduction: putting all the pieces together again. Faseb J. 2006;20:811–827.
   PubMed Web of Science ®Google Scholar
• Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961.
   PubMed Web of Science ®Google Scholar
• O’Riordan TG, Smith V, Raghu G. Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. Chest. 2015;148:1083–1092.
   PubMed Web of Science ®Google Scholar
• Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med. 2014;190:867–878.
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136–151.
   PubMed Web of Science ®Google Scholar
• Raghu G, Anstrom KJ, King TE Jr., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–1977.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med. 2015;21:470–478.
   PubMed Web of Science ®Google Scholar
• Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136.
   PubMed Web of Science ®Google Scholar
• Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One. 2010;5:e8959.
   PubMed Web of Science ®Google Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364:1503–1512.
   PubMed Web of Science ®Google Scholar
• Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One. 2013;8:e70621.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Noth I, Garcia JG, et al. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med. 2011;364:1576–1577.
   PubMed Web of Science ®Google Scholar
• Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet. 2015;47:512–517.
   PubMed Web of Science ®Google Scholar
• Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–2239.
   PubMed Web of Science ®Google Scholar
• Rajasekaran S, Rajaguru P, Sudhakar Gandhi PS. MicroRNAs as potential targets for progressive pulmonary fibrosis. Front Pharmacol. 2015;6:254.
   PubMed Web of Science ®Google Scholar
• Steele MP, Luna LG, Coldren CD, et al. Relationship between gene expression and lung function in idiopathic interstitial pneumonias. BMC Genomics. 2015;16:869.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 2008;5:e62.
   PubMed Web of Science ®Google Scholar
• White ES, Atrasz RG, Hu B, et al. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am J Respir Crit Care Med. 2006;173:112–121.
   PubMed Web of Science ®Google Scholar
• Cigna N, Farrokhi Moshai E, Brayer S, et al. The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am J Pathol. 2012;181:2126–2137.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179.
   PubMed Web of Science ®Google Scholar
• Gunther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev: Off J Eur Respir Soc. 2012;21:152–160.
   PubMedGoogle Scholar
• Bellaye P-S, Kolb M. Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis. BMC Med. 2015;13:176.
   PubMed Web of Science ®Google Scholar
• Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181:254–263.
   PubMed Web of Science ®Google Scholar
• Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014;189:214–222.
   PubMed Web of Science ®Google Scholar
• Kapanci Y, Desmouliere A, Pache JC, et al. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am J Respir Crit Care Med. 1995;152:2163–2169.
   PubMed Web of Science ®Google Scholar
• Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest. 1990;86:1055–1064.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res. 2002;3:3.
   PubMed Web of Science ®Google Scholar
• Bueno M, Lai Y-C, Romero Y, et al. PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest. 2015;125:521–538.
   PubMed Web of Science ®Google Scholar
• Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:838–846.
   PubMed Web of Science ®Google Scholar
• Marinkovic A, Liu F, Tschumperlin DJ. Matrices of physiologic stiffness potently inactivate idiopathic pulmonary fibrosis fibroblasts. Am J Respir Cell Mol Biol. 2013;48:422–430.
   PubMed Web of Science ®Google Scholar
• Cromar GL, Xiong X, Chautard E, et al. Toward a systems level view of the ECM and related proteins: a framework for the systematic definition and analysis of biological systems. Proteins. 2012;80:1522–1544.
   PubMed Web of Science ®Google Scholar
• Huxley-Jones J, Pinney JW, Archer J, et al. Back to basics – how the evolution of the extracellular matrix underpinned vertebrate evolution. Int J Exp Pathol. 2009;90:95–100.
   PubMed Web of Science ®Google Scholar
• Oschman JL. Charge transfer in the living matrix. J Bodyw Mov Ther. 2009;13:215–228.
   PubMedGoogle Scholar
• Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009;326:1216–1219.
   PubMed Web of Science ®Google Scholar
• Friedland JC, Lee MH, Boettiger D. Mechanically activated integrin switch controls alpha5beta1 function. Science. 2009;323:642–644.
   PubMed Web of Science ®Google Scholar
• Schwarz US, Gardel ML. United we stand: integrating the actin cytoskeleton and cell-matrix adhesions in cellular mechanotransduction. J Cell Sci. 2012;125:3051–3060.
   PubMed Web of Science ®Google Scholar
• Eisenberg JL, Safi A, Wei X, et al. Substrate stiffness regulates extracellular matrix deposition by alveolar epithelial cells. Res Rep Biol. 2011;2011:1–12.
   PubMedGoogle Scholar
• Balestrini JL, Chaudhry S, Sarrazy V, et al. The mechanical memory of lung myofibroblasts. Integr Biol: Quant Biosci Nano Macro. 2012;4:410–421.
   Google Scholar
• Rahaman SO, Grove LM, Paruchuri S, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J Clin Invest. 2014;124:5225–5238.
   PubMed Web of Science ®Google Scholar
• Clarke DL, Carruthers AM, Mustelin T, et al. Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes. Fibrogenesis Tissue Repair. 2013;6:20.
   PubMedGoogle Scholar
• Khalil N, O’Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991;5:155–162.
   PubMed Web of Science ®Google Scholar
• Broekelmann TJ, Limper AH, Colby TV, et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A. 1991;88:6642–6646.
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807–1816.
   PubMed Web of Science ®Google Scholar
• Hinz B, Celetta G, Tomasek JJ, et al. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell. 2001;12:2730–2741.
   PubMed Web of Science ®Google Scholar
• Ohta K, Mortenson RL, Clark RA, et al. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995;152:1659–1665.
   PubMed Web of Science ®Google Scholar
• Kulasekaran P, Scavone CA, Rogers DS, et al. Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol. 2009;41:484–493.
   PubMed Web of Science ®Google Scholar
• Chambers RC, Leoni P, Kaminski N, et al. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol. 2003;162:533–546.
   PubMed Web of Science ®Google Scholar
• Desmouliere A, Geinoz A, Gabbiani F, et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103–111.
   PubMed Web of Science ®Google Scholar
• Epa AP, Thatcher TH, Pollock SJ, et al. Normal human lung epithelial cells inhibit transforming growth factor-beta induced myofibroblast differentiation via prostaglandin E2. PLoS One. 2015;10:e0135266.
   Web of Science ®Google Scholar
• Wipff P-J, Rifkin DB, Meister -J-J, et al. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. 2007;179:1311–1323.
   PubMed Web of Science ®Google Scholar
• Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68:155–162.
   PubMed Web of Science ®Google Scholar
• Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2:548–556.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, King TE Jr., Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170:904–910.
   PubMed Web of Science ®Google Scholar
• Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016 Apr 1;193(7):745–752.
   PubMed Web of Science ®Google Scholar
• Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014;9:e86716.
   PubMed Web of Science ®Google Scholar
• Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307:L681–91.
   PubMed Web of Science ®Google Scholar
• Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:e93.
   PubMed Web of Science ®Google Scholar
• Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143:1422–1429.
   PubMed Web of Science ®Google Scholar
• Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 2015;3:473–482.
   PubMed Web of Science ®Google Scholar
• Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113–1130.
   PubMed Web of Science ®Google Scholar
• Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368:2192–2200.
   PubMed Web of Science ®Google Scholar
• Iwasawa T, Asakura A, Sakai F, et al. Assessment of prognosis of patients with idiopathic pulmonary fibrosis by computer-aided analysis of CT images. J Thorac Imaging. 2009;24:216–222.
   PubMed Web of Science ®Google Scholar
• Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J. 2011;38:176–183.
   PubMed Web of Science ®Google Scholar
• Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684–691.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ma SF, Vij R, et al. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15:147.
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–95.
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158:641–649.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185:1044–1048.
   PubMed Web of Science ®Google Scholar
• Karimi-Shah BA, Chowdhury BA. Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372:1189–1191.
   PubMed Web of Science ®Google Scholar
• Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015;191:252–254.
   PubMed Web of Science ®Google Scholar
• Aravena C, Labarca G, Venegas C, et al. Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One. 2015;10:e0140288.
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Bradford WZ, Fagan EA, et al. Sensitivity analyses of the change in FVC in a phase 3 trial of pirfenidone for idiopathic pulmonary fibrosis. Chest. 2015;148:196–201.
   PubMed Web of Science ®Google Scholar
• Nathan S, Albera C, Bradford W, et al. Effect of pirfenidone on ipf-related mortality outcome measures in patients with idiopathic pulmonary fibrosis (ipf): pooled data analysis from the ascend and capacity trials. Chest. 2015;148:391A-391B.
   Web of Science ®Google Scholar
• Behr J, Bendstrup E, Crestani B, et al. Pirfenidone and n-acetylcysteine (nac) for the treatment of idiopathic pulmonary fibrosis (ipf): exploratory efficacy results from the panorama study. Chest. 2015;148:641A-641B.
   Web of Science ®Google Scholar
• Meng H, Xu Y. Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. Drug Des Devel Ther. 2015;9:3369–3376.
   PubMed Web of Science ®Google Scholar
• Onoue S, Seto Y, Kato M, et al. Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis. Pharm Res. 2013;30:1586–1596.
   PubMed Web of Science ®Google Scholar
• Myllarniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur Clin Respir J. 2015 Feb 10;2.
   Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–1392.
   PubMed Web of Science ®Google Scholar
• Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129:794–800.
   PubMed Web of Science ®Google Scholar
• Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42:1322–1331.
   PubMed Web of Science ®Google Scholar
• Ghebremariam YT, Cooke JP, Gerhart W, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369–376.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Moua T, Daniels CE, et al. Idiopathic pulmonary fibrosis: evolving concepts. Mayo Clinic Proc. 2014;89:1130–1142.
   PubMed Web of Science ®Google Scholar
• Allaix ME, Fisichella PM, Noth I, et al. Idiopathic pulmonary fibrosis and gastroesophageal reflux. Implications for treatment. J Gastrointest Surg. 2014;18:100–105. discussion 4-5.
   PubMed Web of Science ®Google Scholar
• Hecker L, Logsdon NJ, Kurundkar D, et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med. 2014;6:231ra47.
   PubMed Web of Science ®Google Scholar
• Egan JJ, Adamali HI, Lok SS, et al. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med. 2011;2011:1–5.
   Google Scholar
• Akram KM, Samad S, Spiteri MA, et al. Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms. Respir Res. 2013;14:9.
   PubMed Web of Science ®Google Scholar
• Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J. 2014;43:1430–1438.
   PubMed Web of Science ®Google Scholar
• Olsen KC, Epa AP, Kulkarni AA, et al. Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules. Am J Respir Cell Mol Biol. 2014;50:737–747.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123:1096–1108.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67:103–117.
   PubMed Web of Science ®Google Scholar
• Hao W, Marsh C, Friedman A. A mathematical model of idiopathic pulmonary fibrosis. PLoS One. 2015;10:e0135097.
   Google Scholar
• Martinez FJ, De Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2093–2101.
   PubMed Web of Science ®Google Scholar
• Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015 Dec 15;192(12):1475–1482.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology. 2015;20:445–452.
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. Faseb J. 2004;18:816–827.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Kolb MR, Duan F, et al. Transforming growth factor-β evokes Ca2+ waves and enhances gene expression in human pulmonary fibroblasts. Am J Respir Cell Mol Biol. 2012;46:757–764.
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008;177:56–65.
   PubMed Web of Science ®Google Scholar
• Puthawala K, Hadjiangelis N, Jacoby SC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177:82–90.
   PubMed Web of Science ®Google Scholar
• STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF). 2015; [ cited 2015 Nov 22], Available from: https://clinicaltrials.gov/ct2/show/NCT01371305
   Google Scholar
• Ponticos M, Holmes AM, Shi-wen X, et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009;60:2142–2155.
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFβ1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40:2174–2182.
   PubMed Web of Science ®Google Scholar
• Raghu G, Scholand MB, De Andrade J, et al. Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): preliminary safety and efficacy results. Eur Respir J. 2012;40:2819.
   Google Scholar
• Tremblay M, Grouix B, Sarra-Bournet F, et al. Pbi-4050, a novel first-in-class anti-fibrotic compound, inhibits CTgf and collagen i production in human alveolar epithelial cells and fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model. Am J Respir Crit Care Med. 1998;189:2014.
   Google Scholar
• Ekert JE, Murray LA, Das AM, et al. Chemokine (CC motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair. 2011;4:1–10.
   PubMedGoogle Scholar
• Martinez F, Brown K, Costabel U, et al. A phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of the safety and efficacy of CNTO 888 (carlumab) in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187:A3376.
   Google Scholar
• Raghu G, Martinez FJ, Brown KK, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015;46:1740–1750.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12:99–106.
   PubMed Web of Science ®Google Scholar
• Hancock A, Armstrong L, Gama R, et al. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998;18:60–65.
   PubMed Web of Science ®Google Scholar
• Lu Y, Azad N, Wang L, et al. Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol. 2010;42:432–441.
   PubMed Web of Science ®Google Scholar
• Knight SD, Adams ND, Burgess JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett. 2010;1:39–43.
   PubMed Web of Science ®Google Scholar
• Funke M, Zhao Z, Xu Y, et al. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol. 2012;46:355–364.
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14:45–54.
   PubMed Web of Science ®Google Scholar
• Dillingh MR, Van Den Blink B, Moerland M, et al. Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. 2013;26:672–676.
   PubMed Web of Science ®Google Scholar
• Burggraaf J, Morrison L, Ginns L, et al. A phase i study of Prm-151 in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187:A5707.
   Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16:1009–1017.
   PubMed Web of Science ®Google Scholar
• Available from: http://www.businesswire.com/news/home/20160105006721/en/
   Google Scholar